Policy & Regulation
Lundbeck to present new Vyepti and bocunebart migraine data at EAN 2026
24 June 2026 - Biopharmaceutical company H. Lundbeck A/S (XCSE: HLUN A) reported on Wednesday that it will present new clinical data from its migraine portfolio at the European Academy of Neurology (E...
Thalia Therapeutics acquires Sanmirna and raises GBP2.75m to advance AML RNA therapy
24 June 2026 - Biotechnology company Thalia Therapeutics plc (AIM: THAT) disclosed on Wednesday that it has agreed to acquire clinical-stage oncology company Sanmirna Therapeutics Inc, adding its lead...
Circio and Tcelltech partner on next-generation CAR-T cell therapy research
24 June 2026 - Circio Holding ASA (OSE:CRNA) a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, announced on Wednesday that it has formed a CAR-T ce...
Essange Reagents and Gentian Diagnostics agree collaboration on diagnostic assay development
24 June 2026 - Gentian Diagnostics (OSE:GENT), a Norway-based developer of in vitro diagnostic reagents, said on Wednesday that it is planning to enter into a collaboration agreement with Essange Reag...
Haisco agrees licensing deal with Nuvectis for two drug candidates
24 June 2026 - Chinese pharmaceutical company Haisco Pharmaceutical Group Co Ltd (SHE:002653) announced on Tuesday that it has entered into an exclusive licensing agreement with Nuvectis, a US biotech...
Psilera introduces new synthetic platform to aid neuroplastogen discovery
24 June 2026 - Psilera, a biopharmaceutical company focused on next-generation psychedelics and neuroplastogens, announced on Tuesday a new method for synthesising novel libraries of next-generation n...